Drug Discovery World

SEPTEMBER 6, 2022

DDW Editor Reece Armstrong looks at the cell and gene therapy landscape, examining the challenges facing developers and the trends we can expect to see throughout the year. . There’s no doubt that cell and gene therapies present some of the most exciting opportunities for emerging drugs. million price point per dose.

Gene Therapy 52

Gene Therapy Gene Manufacturing Medicine 52

XTalks

AUGUST 2, 2023

Meanwhile, BioMarin’s gene therapy Roctavian is approved by the FDA for the treatment of hemophilia A. Onureg (azacitidine), a leukemia therapy, also saw large growth of 70 percent to $124 million in 2022, and the multiple sclerosis drug Zeposia (ozanimod) generated $250 million in 2022, an 87 percent increase.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

Pharmaceutical Technology

MAY 9, 2023

Meanwhile, decentralisation and the Big Data revolution are transforming the way researchers run clinical trials, and previously untapped geographies are emerging as new hubs for future research. Translating Big Data into results Big Data is another cornerstone of the digital revolution.

Clinical Trials 130

Clinical Trials Clinical Trials Trials Big Data 130